Pegfilgrastim biosimilar - Lupin

Drug Profile

Pegfilgrastim biosimilar - Lupin

Alternative Names: Lupifil-P; Pegfilgrastim - Lupin

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lupin
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Febrile neutropenia

Most Recent Events

  • 19 May 2016 Launched for Febrile neutropenia (Adjunctive treatment, In the elderly, Prevention, In adults) in India before May 2016 (SC)
  • 22 Oct 2013 Biomarkers information updated
  • 03 Sep 2013 Registered for prevention of Febrile neutropenia (adjunct to chemotherapy in adults and elderly patients with non-myeloid malignancies) in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top